For research use only, not for therapeutic use.
Fasudil hydrochloride hydrate（Cat No.:I027289）is a potent Rho kinase inhibitor originally developed for treating cerebral vasospasm following subarachnoid hemorrhage. By inhibiting Rho kinase, fasudil promotes vasodilation and improves blood flow, making it beneficial for conditions involving vascular dysfunction. Additionally, it has shown promise in various therapeutic areas, including cardiac and neurological disorders, due to its neuroprotective and anti-inflammatory effects. Ongoing research is exploring its potential applications in treating diseases like ischemic stroke and heart failure. Fasudil’s favorable safety profile further supports its potential use in diverse clinical settings.
| Catalog Number | I027289 |
| CAS Number | 186694-02-0 |
| Synonyms | Eril-S; Fasudil hydrochloride hemihydrate; Fasudil hydrochloride hydrate |
| Molecular Formula | C28H38Cl2N6O5S2 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 5-(1,4-diazepan-1-ylsulfonyl)isoquinoline;hydrate;dihydrochloride |
| InChI | InChI=1S/2C14H17N3O2S.2ClH.H2O/c2*18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14;;;/h2*1,3-5,7,11,15H,2,6,8-10H2;2*1H;1H2 |
| InChIKey | AACOJGPCMIDLEY-UHFFFAOYSA-N |
| SMILES | C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3.C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3.O.Cl.Cl |
| Reference | 1. Shenkar R, Shi C, Austin C, Moore T, Lightle R, Cao Y, Zhang L, Wu M, Zeineddine HA, Girard R, McDonald DA, Rorrer A, Gallione C, Pytel P, Liao JK, Marchuk DA, Awad IA. RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke. 2017 Jan;48(1):187-194. doi: 10.1161/STROKEAHA.116.015013. Epub 2016 Nov 22. PMID: 27879448; PMCID: PMC5183488. |
